IPO - Profile


We are a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Our proprietary platform technology, BAROSTIM, is designed to leverage the power of the brain to address the imbalance of the ANS, which causes HF and other cardiovascular diseases. Our second-generation product, BAROSTIM NEO, is the first and only commercially available neuromodulation device indicated to improve symptoms for patients with HFrEF, or systolic HF.

BAROSTIM NEO provides BAT by sending imperceptible and persistent electrical pulses to baroreceptors located More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$18.00 7,000,000 Positive High 7.9%

Offering Team

  • Legal counsel
  • Faegre and Benson LLP
  • Auditors
  • Grant Thornton LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 29 Jun, 2021

Offer 30 Jun, 2021

Look Ahead

Lock Up Expiry Dec 30, 2021

IPO Terms

Offer Price $18.00
Offer Size 7M

Market Sentiments

Stock Price